摘要目的 评价EUS引导下125I粒子植入联合吉西他滨化疗治疗胰腺癌的临床收益疗效.方法 41例不能手术切除的胰腺癌患者按完全随机法分为放射性125I粒子植入联合吉西他滨化疗组(21例)和单纯吉西他滨化疗组(20例).吉西他滨化疗方案为1 000 mg/m2,1次/周,静脉滴注,连用3周,休息1周;联合组在125I粒子植入后1周行化疗.评价临床受益疗效(CBR).结果 125I粒子联合吉西他滨化疗组临床受益率为57.1%,达到CBR的中位时间为1周,临床受益疗效持续的中位时间为21周;单纯化疗组分别为25%、4周和15周,两组前2项相差非常显著(P<0.05),而临床受益疗效持续的中位时间无显著差异(P>0.05).结论 EUS引导下125I粒子组织间植入联合吉西他滨化疗治疗不能手术切除的胰腺癌的CBR明显优于单纯吉西他滨化疗组.

abstractsObjective To investigate the clinical benefit response (CBR) in treating the unresectable pancreatic carcinoma by applying the EUS guided iodine-125 seed implantation combined with chemotherapy of gemeitabine and comparing chemotherapy of gemcitabine alone. Methods Forty-one patients with unresectable pancreatic carcinoma were randomly divided into two groups, one group (Group A) included 21 cases which underwent EUS-guided iodine-125 seed implantation combined with gemcitabine chemotherapy, the rest 20 cases (Group B) were treated with gemcitabine chemotherapy alone. EUS-guided iodine-125 seed implantation were carried according to the treatment plan system (TPS), following chemotherapy after 1 week. Gemcitabine was administered at the dose of 1 000 mg/m2, through intravenous administration once a week for 3 consecutive weeks every 4 weeks. CBR was assessed. Results CBR of Group A was 57.1% and median time to CBR was 1 week and median duration of CBR was 21 weeks, while CBR of Group B was 25%, and median time to CBR was 4 weeks and median duration of CBR was 15 weeks (P<0.01). Conclusions EUS-guided iodine-125 seed implantation combined with chemotherapy of gemcitabine was superior to gemcitabine chemotherapy alone in the term of CBR in patients with unresectable pancreatic carcinoma.